ESPERION THERAPEUTICS INC (ESPR) Stock Price, Quote, News and Overview
NASDAQ:ESPR - Nasdaq - US29664W1053 - Common Stock - Currency: USD
ESPR Quote, Performance and Key Statistics
1.09
+0.11 (+10.77%)
The current stock price of ESPR is 1.09 USD. In the past month the price decreased by -15.5%. In the past year, price decreased by -47.6%.
ESPR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 59.86 | 780.78B | ||
| JNJ | JOHNSON & JOHNSON | 15.53 | 375.64B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 20.01 | 307.32B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.75 | 225.73B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 19.47 | 224.59B | ||
| MRK | MERCK & CO. INC. | 10.68 | 209.31B | ||
| PFE | PFIZER INC | 7.54 | 137.25B | ||
| SNY | SANOFI-ADR | 14.36 | 135.72B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.89 | 102.91B | ||
| GSK | GSK PLC-SPON ADR | 7.09 | 79.05B | ||
| ZTS | ZOETIS INC | 26.59 | 70.23B | ||
| HLN | HALEON PLC-ADR | 21.84 | 48.25B |
Related stock screener links
About ESPR
Company Profile
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 304 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Company Info
ESPERION THERAPEUTICS INC
3891 Ranchero Drive, Suite 150, Suite 300
Ann Arbor MICHIGAN 48108 US
CEO: Tim M. Mayleben
Employees: 304
Phone: 17348873903
ESPERION THERAPEUTICS INC / ESPR FAQ
What is the stock price of ESPERION THERAPEUTICS INC today?
The current stock price of ESPR is 1.09 USD. The price increased by 10.77% in the last trading session.
What is the ticker symbol for ESPERION THERAPEUTICS INC stock?
The exchange symbol of ESPERION THERAPEUTICS INC is ESPR and it is listed on the Nasdaq exchange.
On which exchange is ESPR stock listed?
ESPR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ESPERION THERAPEUTICS INC stock?
14 analysts have analysed ESPR and the average price target is 6.61 USD. This implies a price increase of 506.51% is expected in the next year compared to the current price of 1.09. Check the ESPERION THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ESPERION THERAPEUTICS INC worth?
ESPERION THERAPEUTICS INC (ESPR) has a market capitalization of 215.98M USD. This makes ESPR a Micro Cap stock.
How many employees does ESPERION THERAPEUTICS INC have?
ESPERION THERAPEUTICS INC (ESPR) currently has 304 employees.
What are the support and resistance levels for ESPERION THERAPEUTICS INC (ESPR) stock?
ESPERION THERAPEUTICS INC (ESPR) has a resistance level at 1.4. Check the full technical report for a detailed analysis of ESPR support and resistance levels.
Is ESPERION THERAPEUTICS INC (ESPR) expected to grow?
The Revenue of ESPERION THERAPEUTICS INC (ESPR) is expected to grow by 6.03% in the next year. Check the estimates tab for more information on the ESPR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ESPERION THERAPEUTICS INC (ESPR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ESPR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ESPR, evaluating the profitability, health, valuation and growth aspects
- ESPERION THERAPEUTICS INC (ESPR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ESPERION THERAPEUTICS INC (ESPR) Sales and EPS estimates to see what analysts future expectations are.
- ESPERION THERAPEUTICS INC (ESPR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ESPERION THERAPEUTICS INC (ESPR) Insider and Institutional Ownership to learn about the owners and their transactions.
- ESPERION THERAPEUTICS INC (ESPR) Stock Chart to make your own analysis
- ESPERION THERAPEUTICS INC (ESPR) Latest news and press-releases to stay up to date.
Does ESPERION THERAPEUTICS INC (ESPR) stock pay dividends?
ESPR does not pay a dividend.
When does ESPERION THERAPEUTICS INC (ESPR) report earnings?
ESPERION THERAPEUTICS INC (ESPR) will report earnings on 2025-05-06, before the market open.
What is the Price/Earnings (PE) ratio of ESPERION THERAPEUTICS INC (ESPR)?
ESPERION THERAPEUTICS INC (ESPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).
What is the Short Interest ratio of ESPERION THERAPEUTICS INC (ESPR) stock?
The outstanding short interest for ESPERION THERAPEUTICS INC (ESPR) is 15.23% of its float. Check the ownership tab for more information on the ESPR short interest.
ESPR Technical Analysis
ESPR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ESPR. ESPR has a bad profitability rating. Also its financial health evaluation is rather negative.
ESPR Financial Highlights
Over the last trailing twelve months ESPR reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 88.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.05% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ESPR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to ESPR. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 92.19% and a revenue growth 6.03% for ESPR